6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled, +342

The Lancet

Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer +4

Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

T Bachelot, C. Bourgier, Claire Cropet, +11

Cancer Research

Breast OncologyPharmacotherapyEndocrine OncologyOncologyClinical Trials +14

Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study

P. Cottu, Véronique D’Hondt, Sylvain Dureau, +17

Annals of Oncology

Minal Breast CancerBreast OncologyUnicancer-eopal StudyGeneration ChemotherapyMedicine +6

Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

PA Kaufman, J-M Ferrero, Hugues Bourgeois, +7

Cancer Research

Breast OncologyHuman GrowthImmunologyGynecologyType 1 +15

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

F-C Bidard, William Jacot, Sylvain Dureau, +18

Cancer Research

Breast OncologyPatient SelectionCancer ManagementPathologyCtc Count +16

Preoperative endosonographic staging of cancer of the cardia

Éric François, Jean-Luc Péroux, Jérôme Mouroux, +4

Abdominal Imaging

Preoperative Endosonographic StagingSurgical OncologyMedicineMinimally Invasive ProcedureSurgery +2

Abstract S3-04: Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer

Grazia Arpino, J-M Ferrero, Juan de la Haba-Rodríguez, +4

Cancer Research

Breast OncologyEstrogen ReceptorFirst-line PatientsPharmacotherapyTumor Biology +15

Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

Hans Wildiers, S-B. Kim, P. LoRusso, +4

Cancer Research

Metastatic Breast CancerOncologyGrade ≥3 AesBreast OncologyClinical Trials +11

Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)

SM Swain, S-B. Kim, J Cortés, +10

Cancer Research

Breast OncologyClinical EndpointPrognosisPathologyPopulation Health Sciences +23

Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): Final results

V. Diéras, Vicente Valero, Steven Limentani, +7

Journal of Clinical Oncology

Tumor BiologyBreast OncologyVivo Tumor ModelsMedicineMbc Pts +13